Northwestern University Feinberg School of Medicine

Center for Translational Metabolism and Health

Publications

Following is a listing of recent and influential publications from the Center for Translational Metabolism and Health. Learn more about our work below.

  1. Gutiérrez OM, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.   Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.  J Am Soc Nephrol. 2005 Jul;16(7):2205-15.
  2. Isakova T, Gutiérrez OM, Shah A, Castaldo L, Holmes J, Lee H, Wolf M.   Postprandial mineral metabolism and secondary hyperparathyroidism in earl CKD.  J Am Soc Nephrol. 2008 Mar; 19(3): 615–623.
  3. Gutiérrez OM,* Mannstadt M,* Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.  N Engl J Med. 2008 Aug 7; 359(6): 584–592.
  4. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M.   Phosphorus binders and survival on hemodialysis.  J Am Soc Nephrol. 2009 Feb; 20(2): 388–396.
  5. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M.  Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease.  Circulation. 2009 May 19; 119(19): 2545–2552.
  6. Gutiérrez OM, Anderson CA, Isakova T, Scialla J, Negrea L, Anderson AH, Bellovich K, Chen J, Robinson N, Ojo A, Lash J, Feldman HI, Wolf M.   Low socioeconomic status associates with higher serum phosphate irrespective of race.  J Am Soc Nephrol. 2010 Nov; 21(11): 1953–1960.
  7. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I.   Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.  J Am Soc Nephrol. 2011 May; 22(5): 956–966.
  8. Isakova T, Wahl P, Vargas G, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash J, Hsu CY, Leonard MB, Wolf M.   FGF23, PTH and phosphorus metabolism in the chronic renal insufficiency cohort.  Kidney Int. 2011 Jun; 79(12): 1370–1378.
  9. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M.   Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.   JAMA. 2011 Jun 15; 305(23): 2432–2439.
  10. Faul C*, Amaral AP*, Oskouei B*, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St. John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, Wolf M.   FGF23 induces left ventricular hypertrophy.  J Clin Invest. 2011 Nov 1; 121(11): 4393–4408.
  11. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan S, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M.   Fibroblast growth factor 23 and inflammation in CKD.  Clin J Am Soc Nephrol. 2012 Jul; 7(7): 1155–1162.
  12. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutiérrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M.   Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.  Clin J Am Soc Nephrol. 2013 Jun 7; 8(6): 1009–1018.
  13. Christov M, Waikar S, Pereira R, Havasi A, Leaf DE, Goltzman D, Divieti Pajevic P, Wolf M, Jüppner H.   Plasma FGF23 levels increase rapidly after acute kidney injury.  Kidney Int. 2013 Oct; 84(4): 776–785.
  14. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald J, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M.   Fibroblast growth factor 23 and cardiovascular events in CKD.  J Am Soc Nephrol. 2014 Feb; 25(2): 349–660.
  15. Wolf M, White KE.  Coupling FGF23 production and cleavage: iron deficiency, rickets, and kidney disease.  Curr Opin Nephrol Hypertens. 2014 Jul;23(4):411-9.
  16. Scialla JJ, Wolf M.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.  Nat Rev Nephrol. 2014 May;10(5):268-78.
  17. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M.  Mineral metabolites and CKD progression in African Americans.  J Am Soc Nephrol. 2012 Dec 28; 24(1): 125–135.
  18. Zisamn AL, Wolf M.  Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease.  Curr Opin Nephrol Hypertens. 2010 Jul;19(4):335-42.
  19. Wolf M, Koch TA, Bregman DB.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.  J Bone Miner Res. 2013 Aug;28(8):1793-803.
  20. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M, Chronic Renal Insufficiency Cohort Study Investigators.  Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.  Kidney Int. 2013 Jun;83(6):1159-68.